Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://thuvienhoasen.org
Are you over 18 and want to see adult content?
A complete backup of https://newvic.ac.uk
Are you over 18 and want to see adult content?
A complete backup of https://activeden.net
Are you over 18 and want to see adult content?
A complete backup of https://acsp.org
Are you over 18 and want to see adult content?
A complete backup of https://justanswer.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://download.geofabrik.de
Are you over 18 and want to see adult content?
A complete backup of https://ecoaquatics.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://pi-top.com
Are you over 18 and want to see adult content?
A complete backup of https://mailshop.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://instaplus.me
Are you over 18 and want to see adult content?
A complete backup of https://palladiumhotelgroup.com
Are you over 18 and want to see adult content?
A complete backup of https://regionsamara.ru
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of chargerforums.com
Are you over 18 and want to see adult content?
A complete backup of shreedesignersaree.com
Are you over 18 and want to see adult content?
A complete backup of brokenwood.com.au
Are you over 18 and want to see adult content?
A complete backup of kevinhartnation.com
Are you over 18 and want to see adult content?
Text
future.
INVESTOR RELATIONS :: CODEXIS, INC. (CDXS)SCALE-UP AND SUPPLYEMAIL ALERTSCONTACTCODEXIS ADDS DR. JENNIFER L. AAKER TO ITS BOARD OFDIRECTORS
Investor Relations. Codexis, Inc. 200 Penobscot Drive Redwood City, CA 94063 T: 650-421-8106 ir@codexis.comCAREERS | CODEXIS
Codexis pays $1,000 to eligible employees who refer an individual whom we hire. Health Club Reimbursement. Codexis wants all employees to enjoy good health and to get regular exercise. We reimburse employees a portion of the cost of joining any gym or fitness program. On-siteFood Program.
CODEX® KRED SCREENING KIT Codex® KRED Screening Kit Screening Protocol document # PRO-006-03 | page 3 of 5 CODEX® KRED SCREENING KIT—SCREENING PROCEDURE P (KREDs 1–19) 1. Weigh out approximately 10 mg of each KRED (1–19) in the kit into separate labelled vials (vials should have at least MANAGEMENT TEAM :: CODEXIS, INC. (CDXS) Rob Wilson, Ph.D. Rob Wilson leads the Performance Enzyme strategic business unit for Codexis and has been with the company since 2006. He has held a variety of business-operational roles at Codexis, across Biotherapeutics and Performance Enzymes, in postings in Europe, Asia and the USA. Prior to joining Codexis, Rob worked for 7 years in CODEX® ATA SCREENING KIT Codex® ATA Screening Kit Screening Protocol document # PRO-002-03 | page 3 of 4 2. Centrifuge each mixture at ~4000 rpm for 2 min to separate the phases or to sediment any precipitated protein. CODEXIS EARNS $6.5 MILLION TECHNOLOGY TRANSFER MILESTONE Codexis expects to receive a $6.5 million payment from GSK for completion of this milestone in the fourth quarter of 2015. Codexis has received a $6 million upfront payment and a $5 million Wave 1 technology transfer milestone payment from GSK since announcing the technology collaboration and license agreement with GSK in July 2014. CODEXIS ANNOUNCES CODEEVOLVER TECHNOLOGY TRANSFER AND Codexis to Receive $5 Million in Upfront Payment. Codexis to Hold Conference Call on Tuesday, August 4, 2015 at 11:00 a.m. Eastern Time. REDWOOD CITY, Calif., Aug. 3, 2015 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the signing of a CodeEvolver ® platform technology license FILED PURSUANT TO RULE 424(B)(5) REGISTRATION NO. 333 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228693 CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED10-K
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ENABLING THE PROMISE OF SYNTHETIC BIOLOGY AGBT 2021 Presentation: Codex® HiFi Hot Start DNA Polymerase. This video provides an overview of our technology and the areas in which we create novel enzymes for life science tools, with a focus on the amplification steps in next-generation sequencing with the Codex ® HiFi Hot Start DNA Polymerase. There are many steps to a healthierfuture.
INVESTOR RELATIONS :: CODEXIS, INC. (CDXS)SCALE-UP AND SUPPLYEMAIL ALERTSCONTACTCODEXIS ADDS DR. JENNIFER L. AAKER TO ITS BOARD OFDIRECTORS
Investor Relations. Codexis, Inc. 200 Penobscot Drive Redwood City, CA 94063 T: 650-421-8106 ir@codexis.comCAREERS | CODEXIS
Codexis pays $1,000 to eligible employees who refer an individual whom we hire. Health Club Reimbursement. Codexis wants all employees to enjoy good health and to get regular exercise. We reimburse employees a portion of the cost of joining any gym or fitness program. On-siteFood Program.
CODEX® KRED SCREENING KIT Codex® KRED Screening Kit Screening Protocol document # PRO-006-03 | page 3 of 5 CODEX® KRED SCREENING KIT—SCREENING PROCEDURE P (KREDs 1–19) 1. Weigh out approximately 10 mg of each KRED (1–19) in the kit into separate labelled vials (vials should have at least MANAGEMENT TEAM :: CODEXIS, INC. (CDXS) Rob Wilson, Ph.D. Rob Wilson leads the Performance Enzyme strategic business unit for Codexis and has been with the company since 2006. He has held a variety of business-operational roles at Codexis, across Biotherapeutics and Performance Enzymes, in postings in Europe, Asia and the USA. Prior to joining Codexis, Rob worked for 7 years in CODEX® ATA SCREENING KIT Codex® ATA Screening Kit Screening Protocol document # PRO-002-03 | page 3 of 4 2. Centrifuge each mixture at ~4000 rpm for 2 min to separate the phases or to sediment any precipitated protein. CODEXIS EARNS $6.5 MILLION TECHNOLOGY TRANSFER MILESTONE Codexis expects to receive a $6.5 million payment from GSK for completion of this milestone in the fourth quarter of 2015. Codexis has received a $6 million upfront payment and a $5 million Wave 1 technology transfer milestone payment from GSK since announcing the technology collaboration and license agreement with GSK in July 2014. CODEXIS ANNOUNCES CODEEVOLVER TECHNOLOGY TRANSFER AND Codexis to Receive $5 Million in Upfront Payment. Codexis to Hold Conference Call on Tuesday, August 4, 2015 at 11:00 a.m. Eastern Time. REDWOOD CITY, Calif., Aug. 3, 2015 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the signing of a CodeEvolver ® platform technology license FILED PURSUANT TO RULE 424(B)(5) REGISTRATION NO. 333 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228693 CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED10-K
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).ABOUT US | CODEXIS
We are committed to improving human health through measures such as improving life science tools, enabling diagnostic innovations, and developing better biotherapeutics.We support the rare disease community by sharing professionals at worldwide conferences and hosting rare disease awareness events for staff to directly correspond with patients, clinicians, and advocacy leaders.CODEEVOLVER®
Our proprietary CodeEvolver ® protein engineering technology is unlike anything else on the market today, and its exceptional capabilities are available to your in-house scientific staff. Representing state-of-the-art advances in five key areas — artificial intelligence, biology, fermentation, chemistry and high-throughput robotics — CodeEvolver ® enables the rapid development of highlyCAREERS | CODEXIS
Codexis pays $1,000 to eligible employees who refer an individual whom we hire. Health Club Reimbursement. Codexis wants all employees to enjoy good health and to get regular exercise. We reimburse employees a portion of the cost of joining any gym or fitness program. On-siteFood Program.
PARTNERS | CODEXIS
Nestlé Health Science (NHSc), a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutrition therapy to change the course of health for consumers, patients and its partners in health care. In 2017, Codexis and Nestlé Health Science entered into a strategic collaboration for multiple projects accessing Codexis’ CodeEvolver ® protein engineering CODEX® ERED SCREENING KIT Codex® ERED Screening Kit Screening Protocol document # PRO-004-03 | page 3 of 3 Codexis, Inc. 200 Penobscot Drive, Redwood City, CA 94063 USA www.codexis.com | sales@codexis.com | DEVELOPMENT OF A PROTEASE STABLE PHENYLALANINE AMMONIA Development of a Protease Stable Phenylalanine Ammonia Lyase as an Orally Administered Enzyme Therapy for Potential Treatment of PKU. Phenylketonuria (PKU) is caused by a mutation in phenylalanine hydroxylase (PAH), which metabolizes phenylalanine (Phe) to tyrosine. The pathophysiology of PKU is linked to the toxic effects of excessPhe in the
ENGINEERING AN AMINE TRANSAMINASE FOR THE PRODUCTION OF A Engineering an Amine Transaminase for the Efficient Production of a Chiral Sacubitril Precursor. Abstract: An amine transaminase was engineered for the efficient production of a chiral precursor tosacubitril,
(2R,4S)-5-(-4-yl)-4-amino-2-methylpentanoic acid, a key component in the blockbuster heart failure drug Entresto.Starting from an enzyme with trace activity and CODEXIS NAMED AS ONE OF THE NATION’S BEST & BRIGHTEST Codexis is pleased to announce we’ve been selected as one of the nation’s Best and Brightest Companies to Work For ®.. December 18, 2017– Warren, MI — The National Association for Business Resources has named the Best and Brightest Companies To Work For ® in the Nation. (See following list of winners.The 2017 national winning companies were assessed by an independent CODEXIS ANNOUNCES CODEEVOLVER TECHNOLOGY TRANSFER AND Codexis to Receive $5 Million in Upfront Payment. Codexis to Hold Conference Call on Tuesday, August 4, 2015 at 11:00 a.m. Eastern Time. REDWOOD CITY, Calif., Aug. 3, 2015 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the signing of a CodeEvolver ® platform technology license AN ENGINEERED DNA LIGASE FOR EFFICIENT CONVERSION OF INPUT An Engineered DNA Ligase for Efficient Conversion of Input DNA During NGS Library Preparation Results www.codexis.com Next-generation sequencing technologies have been applied in the field ENABLING THE PROMISE OF SYNTHETIC BIOLOGY AGBT 2021 Presentation: Codex® HiFi Hot Start DNA Polymerase. This video provides an overview of our technology and the areas in which we create novel enzymes for life science tools, with a focus on the amplification steps in next-generation sequencing with the Codex ® HiFi Hot Start DNA Polymerase. There are many steps to a healthierfuture.
ABOUT US | CODEXIS
We are committed to improving human health through measures such as improving life science tools, enabling diagnostic innovations, and developing better biotherapeutics.We support the rare disease community by sharing professionals at worldwide conferences and hosting rare disease awareness events for staff to directly correspond with patients, clinicians, and advocacy leaders. PHARMACEUTICAL MANUFACTURING Challenge: Januvia ® is a blockbuster drug for the treatment of Type 2 diabetes, manufactured by Merck.As the drug achieved increased commercial penetration, Merck was faced with building an additional manufacturing facility to keep up with demand,CAREERS | CODEXIS
Codexis pays $1,000 to eligible employees who refer an individual whom we hire. Health Club Reimbursement. Codexis wants all employees to enjoy good health and to get regular exercise. We reimburse employees a portion of the cost of joining any gym or fitness program. On-siteFood Program.
INVESTOR RELATIONS :: CODEXIS, INC. (CDXS) Investor Relations. Codexis, Inc. 200 Penobscot Drive Redwood City, CA 94063 T: 650-421-8106 ir@codexis.com CODEX® KRED SCREENING KIT Codex® KRED Screening Kit Screening Protocol document # PRO-006-03 | page 3 of 5 CODEX® KRED SCREENING KIT—SCREENING PROCEDURE P (KREDs 1–19) 1. Weigh out approximately 10 mg of each KRED (1–19) in the kit into separate labelled vials (vials should have at least MANAGEMENT TEAM :: CODEXIS, INC. (CDXS) Rob Wilson, Ph.D. Rob Wilson leads the Performance Enzyme strategic business unit for Codexis and has been with the company since 2006. He has held a variety of business-operational roles at Codexis, across Biotherapeutics and Performance Enzymes, in postings in Europe, Asia and the USA. Prior to joining Codexis, Rob worked for 7 years in DEVELOPMENT OF A PROTEASE STABLE PHENYLALANINE AMMONIA Development of a Protease Stable Phenylalanine Ammonia Lyase as an Orally Administered Enzyme Therapy for Potential Treatment of PKU. Phenylketonuria (PKU) is caused by a mutation in phenylalanine hydroxylase (PAH), which metabolizes phenylalanine (Phe) to tyrosine. The pathophysiology of PKU is linked to the toxic effects of excessPhe in the
CODEXIS NAMED AS ONE OF THE NATION’S BEST & BRIGHTEST Codexis is pleased to announce we’ve been selected as one of the nation’s Best and Brightest Companies to Work For ®.. December 18, 2017– Warren, MI — The National Association for Business Resources has named the Best and Brightest Companies To Work For ® in the Nation. (See following list of winners.The 2017 national winning companies were assessed by an independent 10-K - IR.CODEXIS.COM Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ENABLING THE PROMISE OF SYNTHETIC BIOLOGY AGBT 2021 Presentation: Codex® HiFi Hot Start DNA Polymerase. This video provides an overview of our technology and the areas in which we create novel enzymes for life science tools, with a focus on the amplification steps in next-generation sequencing with the Codex ® HiFi Hot Start DNA Polymerase. There are many steps to a healthierfuture.
ABOUT US | CODEXIS
We are committed to improving human health through measures such as improving life science tools, enabling diagnostic innovations, and developing better biotherapeutics.We support the rare disease community by sharing professionals at worldwide conferences and hosting rare disease awareness events for staff to directly correspond with patients, clinicians, and advocacy leaders. PHARMACEUTICAL MANUFACTURING Challenge: Januvia ® is a blockbuster drug for the treatment of Type 2 diabetes, manufactured by Merck.As the drug achieved increased commercial penetration, Merck was faced with building an additional manufacturing facility to keep up with demand,CAREERS | CODEXIS
Codexis pays $1,000 to eligible employees who refer an individual whom we hire. Health Club Reimbursement. Codexis wants all employees to enjoy good health and to get regular exercise. We reimburse employees a portion of the cost of joining any gym or fitness program. On-siteFood Program.
INVESTOR RELATIONS :: CODEXIS, INC. (CDXS) Investor Relations. Codexis, Inc. 200 Penobscot Drive Redwood City, CA 94063 T: 650-421-8106 ir@codexis.com CODEX® KRED SCREENING KIT Codex® KRED Screening Kit Screening Protocol document # PRO-006-03 | page 3 of 5 CODEX® KRED SCREENING KIT—SCREENING PROCEDURE P (KREDs 1–19) 1. Weigh out approximately 10 mg of each KRED (1–19) in the kit into separate labelled vials (vials should have at least MANAGEMENT TEAM :: CODEXIS, INC. (CDXS) Rob Wilson, Ph.D. Rob Wilson leads the Performance Enzyme strategic business unit for Codexis and has been with the company since 2006. He has held a variety of business-operational roles at Codexis, across Biotherapeutics and Performance Enzymes, in postings in Europe, Asia and the USA. Prior to joining Codexis, Rob worked for 7 years in DEVELOPMENT OF A PROTEASE STABLE PHENYLALANINE AMMONIA Development of a Protease Stable Phenylalanine Ammonia Lyase as an Orally Administered Enzyme Therapy for Potential Treatment of PKU. Phenylketonuria (PKU) is caused by a mutation in phenylalanine hydroxylase (PAH), which metabolizes phenylalanine (Phe) to tyrosine. The pathophysiology of PKU is linked to the toxic effects of excessPhe in the
CODEXIS NAMED AS ONE OF THE NATION’S BEST & BRIGHTEST Codexis is pleased to announce we’ve been selected as one of the nation’s Best and Brightest Companies to Work For ®.. December 18, 2017– Warren, MI — The National Association for Business Resources has named the Best and Brightest Companies To Work For ® in the Nation. (See following list of winners.The 2017 national winning companies were assessed by an independent 10-K - IR.CODEXIS.COM Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).ABOUT US | CODEXIS
We are committed to improving human health through measures such as improving life science tools, enabling diagnostic innovations, and developing better biotherapeutics.We support the rare disease community by sharing professionals at worldwide conferences and hosting rare disease awareness events for staff to directly correspond with patients, clinicians, and advocacy leaders.SCALE UP AND SUPPLY
Cost-effective. With more efficient processes that use fewer manufacturing steps, have faster reaction times and deliver higher product yields, engineered enzymes can lower costs and improve profitability. Dependable. Codexis ensures delivery from a flexible, integrated supply chain, enabling competitive lead times and surety ofsupply.
INDUSTRIAL APPLICATIONS Tailored enzymes outperform. Codexis’ engineered enzymes can increase yields, reduce cycle times, and enable cost-effective processes. We work with our partners from conception through to commercialization, so whether you need enzymes for the lab, or inPARTNERS | CODEXIS
Nestlé Health Science (NHSc), a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutrition therapy to change the course of health for consumers, patients and its partners in health care. In 2017, Codexis and Nestlé Health Science entered into a strategic collaboration for multiple projects accessing Codexis’ CodeEvolver ® protein engineering CODEX® HIFI HOT START DNA POLYMERASE Fully optimized and formulated for next-generation sequencing workflows, the Codex ® HiFi Hot Start DNA Polymerase allows developers of NGS library preparation kits or diagnostic molecular assays to create kits that will give customers more confidence in their data, reducing the number of total reads required, even for low sample inputs, or at decreased depths of coverage. DEVELOPMENT OF A PROTEASE STABLE PHENYLALANINE AMMONIA Development of a Protease Stable Phenylalanine Ammonia Lyase as an Orally Administered Enzyme Therapy for Potential Treatment of PKU. Phenylketonuria (PKU) is caused by a mutation in phenylalanine hydroxylase (PAH), which metabolizes phenylalanine (Phe) to tyrosine. CODEX® ERED SCREENING KIT Codex® ERED Screening Kit Screening Protocol document # PRO-004-03 | page 3 of 3 Codexis, Inc. 200 Penobscot Drive, Redwood City, CA 94063 USA www.codexis.com | sales@codexis.com | CODEXIS ANNOUNCES CODEEVOLVER TECHNOLOGY TRANSFER AND Codexis to Receive $5 Million in Upfront Payment. Codexis to Hold Conference Call on Tuesday, August 4, 2015 at 11:00 a.m. Eastern Time. REDWOOD CITY, Calif., Aug. 3, 2015 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the signing of a CodeEvolver ® platform technology license CODEXIS EARNS $6.5 MILLION TECHNOLOGY TRANSFER MILESTONE Codexis expects to receive a $6.5 million payment from GSK for completion of this milestone in the fourth quarter of 2015. Codexis has received a $6 million upfront payment and a $5 million Wave 1 technology transfer milestone payment from GSK since announcing the technology collaboration and license agreement with GSK in July 2014.CDXS-2014.12.31-10K
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). skip to Main Content* Why Codexis
* Company
* About Us
* Why Codexis
* Partners
* Leadership
* Board of Directors* Industries
* Pharmaceuticals
* Biotherapeutics
* Food & Beverage
* Molecular Diagnostics* Resources
* Scientific Showcase * Awards & Recognition* News
* Events
* What You Need
* Protein Engineering * CodeEvolver® Licensing * Scale-up and Supply* Screening Kits
* Contact
* Careers
* Investors
* Search
Open Mobile Menu
UNLOCK THE
POWER OF PROTEINS®
Apply our revolutionary CodeEvolver® platform technology to deliver high-performing enzymes and customized solutions in a wide array ofapplications.
Watch the video
PHARMACEUTICALS
Improve production processes with state-of-the-art enzymes.Learn More
BIOTHERAPEUTICS
Create novel therapeutic proteins with highly optimized performance.Learn More
FOOD & BEVERAGE
Impact product quality and profitability with expert proteinengineering.
Learn More
MOLECULAR DIAGNOSTICS Accelerate next-generation sequencing with powerful enzyme solutions.Learn More
“The partnership with Codexis strengthens our footprint in the enzyme field, a fast-developing part of the nutritional therapy innovation frontier that is changing the way we manage our health.”Greg Behar, CEO
Nestlé Health Science “We chose the Codexis platform after a thorough evaluation of the enzyme evolution landscape. Codexis has a significant track record of delivering evolved biocatalysts for pharmaceutical and fine chemical applications over an extended period of time.” Doug Fuerst, Technology Development Lead, Synthetic BiologyGlaxoSmithKline
“We view Codexis as an extension of our internal research and development programs at Tate & Lyle and are excited about the opportunities which this partnership brings to deliver new and innovative food ingredients to the market.” Michael Harrison, Senior Vice President of New Product DevelopmentTate & Lyle
“ process, which won a 2010 Presidential Green Chemistry Award, increased sitagliptin yield, cut back on production steps, and reduced water use and waste. The advance led to a threefold increase in productivity and helped us avoid the cost of building a second factory to meet rising demand for Januvia.” R.P. "Skip" Volante, Vice President of R&DMerck
LATEST NEWS
26Sep 2019
CODEXIS SPREADING THE PROMISE OF ENGINEERED PROTEINS AT SYNBIOBETASUMMIT
REDWOOD CITY, Calif. –(BUSINESS WIRE)–Sep. 26, 2019– Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, is contributing resources and expertise to communicate protein engineering’s vast potential at SynBioBeta’s Global Synthetic Biology Summit in San Francisco , Oct. 1–3.read more26Sep 2019
CODEXIS TO PRESENT AT THE 2019 CANTOR FITZGERALD GLOBAL HEALTHCARECONFERENCE
REDWOOD CITY, Calif. , Sept. 26, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4 at 12:00 p.m.Eastern…read more
06Aug 2019
CODEXIS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS Product revenue up 68%; R&D revenue spread over wider base of customers and markets Conference call begins at 4:30 pm Eastern time today REDWOOD CITY, Calif. , Aug. 06, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein…read more06Aug 2019
CODEXIS NAMES ROSS TAYLOR SENIOR VICE PRESIDENT AND CHIEF FINANCIALOFFICER
CFO Gordon Sangster announces retirement REDWOOD CITY, Calif. , Aug. 06, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces the appointment of Ross Taylor as Senior Vice President and Chief Financial Officer effectiveAugust…read more
30Jul 2019
CODEXIS TO HOLD SECOND QUARTER 2019 CONFERENCE CALL ON AUGUST 6 REDWOOD CITY, Calif. , July 30, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2019 financial results after market close on Tuesday, August 6, 2019 . Codexis management…read more* 1
* 2
* 3
* 4
* …
* 29
* Next
twitter linkedin
Contact Investors
Careers
2019 Codexis. All rights reserved. LegalSite Credits
Back To Top
Close search
Search Search Submit* Why Codexis
* Company
* About Us
* Why Codexis
* Partners
* Leadership
* Board of Directors* Industries
* Pharmaceuticals
* Biotherapeutics
* Food & Beverage
* Molecular Diagnostics* Resources
* Scientific Showcase * Awards & Recognition* News
* Events
* What You Need
* Protein Engineering * CodeEvolver® Licensing * Scale-up and Supply* Screening Kits
* Contact
* Careers
* Investors
* Search
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0